Drugs / HIV CTL MEP
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00195234 | Dec 2004 → Feb 2007 | HIV infectious disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00076037 | Apr 2004 → Jun 2006 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HIV CTL MEP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00195234 ↗ |
| Modality | Vaccine | “HIV CTL MEP vaccine developed as part of a prime-boost strategy” NCT00076037 ↗ |